Neuron23
Focus: Neuron23 is an AI-driven drug discovery biotech focused on neurology, operating at Series C+ stage from South San Francisco. The company leverages computational methods to identify novel neurological therapeutics.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
0
About Neuron23
AI assessmentNot HiringNo open roles listed right now. Follow Neuron23 to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease
Parkinson DiseaseClinical Trials (1)
NCT04893083A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease
N/AHelp build intelligence for Neuron23
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.